Giuseppe Leone: This Review by Offidani’s Group Compares Clinical Trials and Outlines Prospects
LABORATORY Professionals International reposted Giuseppe Leone’s post on LinkedIn:
“At major international conferences in 2024, important data emerged on new approaches capable of improving outcomes even in high-risk or very advanced disease. Upfront quadruplet combinations, including anti-CD38 monoclonal antibodies, have proven to be the best therapy in terms of depth of response and long-term efficacy in both transplant-eligible and ineligible patients. Despite the introduction of these therapies, high-risk multiple myeloma (MM) remains challenging to treat. This review by Offidani’s group compares clinical trials and outlines prospects.”
Title: Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES
Authors: Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Read more here.
Stay updated with Hemostasis Today.
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar